A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines
Open Access
- 14 February 2022
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 53 (4), 798-823
- https://doi.org/10.1007/s11239-021-02626-w
Abstract
Reports of thrombotic response after receiving COVID-19 Adenoviral-Vector Based Vaccines raise concerns about vaccine-induced thrombotic thrombocytopenia (VITT); therefore, we conduct this systematic review to report susceptible demographics outcomes, commonalities, and prognosis of reporting cases. We identified published articles by searching PubMed, SCOPUS, and Web of Science from December 2020 till May 2021, with an updated search in September 2021. All case reports and case series reporting thrombotic response after receiving COVID-19 Adenoviral-Vector Based Vaccines were eligible for including. In addition, two authors independently extracted data and assessed the quality of the included studies. A total of 157 patients with thrombotic events after the ChAdOx1 nCoV-19 vaccine and 16 patients with thrombotic events after Ad26.COV2. S vaccine was included in our study. 72% of the ChAdOx1 nCoV-19 cases were females, while in Ad26.COV2.S subgroup, all reported patients were females. The commonest presentations were deep vein thrombosis 20 (12.7%) and cerebral venous sinus thrombosis 18 (11.5%) in the ChAdOx1 nCoV-19 subgroup while cerebral venous sinus thrombosis 14 (87.5%) and pulmonary embolism 2 (12.5%) in the Ad26.COV2. S subgroup. In this study, we described the certain demographics associated with VITT and the clinical presentations of those cases in the ChAdOx1 nCoV-19 and Ad26.COV2. S vaccines. Young individuals, particularly females, may be more susceptible to VITT, and future studies should seek to confirm this association. In addition, the clinical presentation of VITT commonly includes cerebral thrombi, pulmonary embolism, and deep venous thrombosis, but other presentations are also possible, highlighting the importance of clinical vigilance in recent vaccine recipients.Keywords
This publication has 66 references indexed in Scilit:
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopeniaBlood Advances, 2018
- The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC studyBMC Family Practice, 2016
- It could be a ‘Golden Goose’: a qualitative study of views in primary care on an emergency admission risk prediction tool prior to implementationBMC Family Practice, 2016
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition)Journal of Chinese Integrative Medicine, 2009
- Heparin-induced thrombocytopenia (an overview)International Journal of Clinical Practice, 2006
- Think of HITHematology, 2006
- Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized miceGene Therapy, 2005
- Letters to the EditorActa Neurochirurgica, 2004
- Heparin-Induced ThrombocytopeniaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2002